Ronaxan 100 mg tablet

Country: Ireland

Language: English

Source: HPRA (Health Products Regulatory Authority)

Active ingredient:

Doxycycline

Available from:

Merial Animal Health Limited

ATC code:

QJ01AA02

INN (International Name):

Doxycycline

Dosage:

100 mg/tablet

Pharmaceutical form:

Tablet

Prescription type:

POM: Prescription Only Medicine as defined in relevant national legislation

Therapeutic group:

Dogs

Therapeutic area:

doxycycline

Therapeutic indications:

Antibacterial

Authorization status:

Authorised

Authorization date:

1900-01-01

Summary of Product characteristics

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Ronaxan 100 mg tablet
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains
ACTIVE SUBSTANCE :
Doxycycline
100 mg
(as doxycycline hyclate)
For full list of excipients, see section 6.1
3 PHARMACEUTICAL FORM
Round, biconvex, light yellow to yellow scored tablet. The tablets can
be divided into equal parts.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Dogs.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Treatment of respiratory tract infections including rhinitis,
tonsillitis and bronchopneumonia in dogs due to organisms
sensitive to doxycycline including:_ Pasteurella_ spp.,_ Bordetella
bronchiseptica_,_ Staphylococcus aureus_ and other
_Staphylococcus_ spp, and_ Streptococcus_ spp.
Treatment of arthropod-borne_ Ehrlichia canis_ infection.
4.3 CONTRAINDICATIONS
Do not use in pregnant animals.
Do not use in known cases of hypersensitivity to the active
ingredient.
Vomiting, oesophagitis and oesophageal ulcerations have been reported
as side effects following doxycycline therapy,
and Ronaxan should not therefore be administered to patients with
dysphagia or diseases accompanied by vomiting.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
None known.
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_
_ _
_P_
_r_
_i_
_n_
_t_
_e_
_d_
_ _
_2_
_5_
_/_
_1_
_1_
_/_
_2_
_0_
_1_
_5_
_C_
_R_
_N_
_ _
_7_
_0_
_2_
_2_
_3_
_4_
_4_
_p_
_a_
_g_
_e_
_ _
_n_
_u_
_m_
_b_
_e_
_r_
_:_
_ _
_1_
4.5 SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE IN A